Latest publications

Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2). Simpson E, Fernández-Peñas P, De Bruin-Weller M, Lio PA, Chu CY, Ezzedine K et al. Adv Ther 2024 Sep 09

Reply to Sujoy Khan. Van der Rijst LP, De Winter-de Groot KM, De Bruin-Weller MS, De Graaf M et al. Pediatr Allergy Immunol 2024 Aug; 35(8):e14222

Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis. Boesjes CM, Kamphuis E, De Graaf M, Spekhorst LS, Haeck I, Van der Gang LF et al. JAMA Dermatol 2024 Aug 07

More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis. Blauvelt A, Eyerich K, Irvine AD, De Bruin-Weller M, Kwatra SG, Gooderham M et al. Dermatol Ther (Heidelb) 2024 Sep; 14(9):2621-2630

Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients. Van der Rijst LP, Hilbrands MS, Zuithoff NPA, De Bruin-Weller MS, Knulst AC, Le TM et al. Clin Transl Allergy 2024 Jul; 14(7):e12381

Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation. Soegiharto R, Alizadeh Aghdam M, Sørensen JA, Van Lindonk E, Bulut Demir F, Porras NM et al. JAMA Dermatol 2024 Jul 17

Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations. Gooderham MJ, De Bruin-Weller M, Weidinger S, Cork MJ, Eichenfield LF, Simpson EL et al. Dermatol Ther (Heidelb) 2024 Aug; 14(8):2285-2296

Performance of high-dose omalizumab in chronic urticaria is predicted by initial improvement to standard dose. Simons JVL, Soegiharto R, Knulst AC, Van den Reek JMPA, Röckmann H et al. J Allergy Clin Immunol Pract 2024 Jun 19

The effect of subcutaneous and sublingual birch pollen immunotherapy on birch pollen-related food allergy: a systematic review. Kallen EJJ, Welsing PMJ, Löwik JM, Van Ree R, Knulst AC, Le TM et al. Front Allergy 2024; 5:1360073

Effect of dupilumab on asthma and aeroallergen sensitization in pediatric atopic dermatitis patients: Results of the BioDay registry. Rijst LPV, Groot KMW, Zuithoff NPA, De Bruin-Weller MS, De Graaf M et al. Pediatr Allergy Immunol 2024 Jun; 35(6):e14178

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib. Kwatra SG, De Bruin-Weller M, Silverberg JI, Lio P, Deleuran M, Aydin H et al. Acta Derm Venereol 2024 May 06; 104:adv18452

Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis. Simpson EL, De Bruin-Weller M, Hong HC, Staumont-Sallé D, Blauvelt A, Eyerich K et al. Dermatol Ther (Heidelb) 2024 May; 14(5):1145-1160

Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2). Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, De Bruin-Weller MS, Ständer S et al. Dermatol Ther (Heidelb) 2024 May; 14(5):1127-1144

The pleiotropic role of interleukin-13 in the pathogenesis of atopic dermatitis. Dekkers C, De Bruin-Weller M et al. Br J Dermatol 2024 Aug 14; 191(3):316-317

Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry. Zhang J, Boesjes CM, Loman L, Kamphuis E, Romeijn MLE, Spekhorst LS et al. J Am Acad Dermatol 2024 Aug; 91(2):300-311